Licensing partnership in Saudi Arabia for Dapsone 5% Gel Melbourne, Australia; 31 July 2025; Acrux Limited (ASX: ACR) Acrux has executed a Sales, Marketing, Distribution and License Agreement with Servacure Trading W.L.L. (‘Servacure’) for Dapsone 5%, Gel for Saudi Arabia. Dapsone 5%, Gel was developed Acrux and was successfully launched through a licensee in […]
ASX Release: 23 January 2023 Melbourne, Australia; Acrux Limited (ASX:ACR) Link Here: Acrux today announced that it has concluded an agreement with Gedeon Richter Plc., one of its manufacturing and distribution partners, for Gedeon Richter to buy out the future royalties of Lenzetto® for contracted territories for EUR4.10 million, which at current rates of exchange […]
Melbourne, Australia – 8 August 2022 Link here : Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the US Food and Drug Administration (FDA) has accepted for review Acrux’s application for a generic version (Abbreviated New Drug Application or ‘ANDA’) of cold sore treatment, Acyclovir Cream, 5%. Key Highlights Acrux has […]
Biomedical projects at the cutting edge of innovation will receive a $25m cash injection, in a boost for next-gen medicine including stem cell research, new treatments for autism and a technology that allows medicine to be taken through the skin. The $25m investment through the federal Biomedical Translation Fund will potentially benefit thousands of Australians […]
Melbourne, Australia; 28 July 2021: Acrux Limited (ASX:ACR) (‘Acrux’ or the ‘Company’) is pleased to announce that the US Food and Drug Administration (‘FDA’) has approved its generic version of EMLA® (Lidocaine 2.5% and Prilocaine 2.5%) Cream. In June 2019, Acrux submitted an ANDA to seek approval from the FDA to market its generic version […]
Melbourne, Australia; 22 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the US Food and Drug Administration (FDA) has granted approval of the Company’s generic version of Jublia® (efinaconazole) topical solution, 10%. Key Points FDA’s approval of the application represents an important milestone for Acrux, being its second approval […]
Melbourne, Australia; 8 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) today announced that Almirall LLC has initiated patent litigation against Acrux in the U.S. District Court for the District of New Jersey, regarding the Company’s Paragraph IV Abbreviated New Drug Application (ANDA) for Dapsone Gel 7.5% (a generic version of Aczone® Gel, 7.5%), […]
Melbourne, Australia; 4 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce Mr Don Brumley has joined the Board as a Non-executive Director. Mr Brumley has 30 years’ experience as a senior partner of Ernst & Young, Oceania. He has extensive experience in IPOs, transactions and audit. Mr Brumley has advised […]
Link to Full Article Melbourne, Australia; 31 May 2021: As announced on 30 April 2021 Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to confirm that the Company’s 100% owned investee company Acrux Pharma Pty Ltd has received approval from AusIndustry for an Advance and Overseas Finding application. The finding covers financial years 2018/19, […]
Link to Full Article MoneyTalks is Stockhead’s regular recap of the ASX stocks and sectors that fund managers and analysts are looking at right now. Today we hear from BioScience Managers’ managing partner Dr Graham Crooke. BioScience Managers is an Australian life sciences investor established in 2003 and has a solid investment record making over 200 investments across […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: